GlassScriptPhysician profile
Rimantas Zalepuga
NPI 1316977499
$33,686.07
in general payments reported to CMS, 2019-2025
34 companies · $1,904 in 2025
The $1,904 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $517 · 2021: $1,291 · 2022: $1,355 · 2023: $1,382 · 2024: $27K · 2025: $1,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $25K · Food and Beverage: $4,825 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $25,213.70 |
| Food and Beverage | $4,825.36 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $25,235.81 | 2019-2024 | Gastrointestinal Videoscope |
| Abbvie INC. | $4,033.26 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Qol Medical, LLC | $940.64 | 2019-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $397.90 | 2024-2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $364.10 | 2020-2023 | |
| Intra-Sana Laboratories | $295.97 | 2021-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Aimmune Therapeutics, INC. | $245.53 | 2024-2025 | Vowst, Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $239.37 | 2019-2025 | Entyvio |
| Celgene Corporation | $226.34 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $221.80 | 2019-2025 | Livdelzi |
| Janssen Biotech, INC. | $195.09 | 2021-2025 | Simponi Aria, Simponi, Stelara |
| Pfizer INC. | $187.37 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.08 | 2019-2024 | Relistor |
| Intercept Pharmaceuticals, INC. | $133.25 | 2020-2023 | Ocaliva |
| Axonics, INC. | $92.38 | 2024 | Axonics |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valencia Technologies Corporation | $78.32 | 2025 | Ecoin Device Kit |
| Ardelyx, INC. | $77.30 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $62.51 | 2021-2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $59.99 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $57.77 | 2019 | |
| Boston Scientific Corporation | $53.83 | 2019-2023 | Resolution 360 Ultra Clip |
| Regeneron Healthcare Solutions, INC. | $50.05 | 2023-2024 | Dupixent |
| Daiichi Sankyo INC. | $32.47 | 2021 | |
| Novo Nordisk INC | $29.76 | 2025 | Wegovy |
| Mauna Kea Technologies, INC. | $28.39 | 2022 | |
| Medtronic, INC. | $27.82 | 2025 | Interstim |
| Thd America, INC. | $26.41 | 2022 | |
| Merck Sharp & Dohme LLC | $23.95 | 2024 | Dificid |
| Shionogi INC | $22.67 | 2019 | |
| Lilly USA, LLC | $21.30 | 2024 | Omvoh |
| Horizon Therapeutics Plc | $20.42 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.37 | 2024 | Givlaari |
| Redhill Biopharma INC. | $15.12 | 2020 | |
| Allergan, INC. | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rimantas Zalepuga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.